Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in IntangiblesChange in IntangiblesChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesChange in TaxesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionDividends Paid - CommonDividends Paid - CommonFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iradimed (IRMD) Net Cash Flow (2016 - 2026)

Iradimed has reported Net Cash Flow over the past 14 years, most recently at $5.2 million for Q1 2026.

  • Quarterly Net Cash Flow rose 374.04% to $5.2 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $6.0 million through Mar 2026, up 16.13% year-over-year, with the annual reading at -$1.1 million for FY2025, 143.5% down from the prior year.
  • Net Cash Flow was $5.2 million for Q1 2026 at Iradimed, up from -$5.4 million in the prior quarter.
  • Over five years, Net Cash Flow peaked at $5.2 million in Q1 2026 and troughed at -$15.2 million in Q1 2023.
  • The 5-year median for Net Cash Flow is $2.4 million (2022), against an average of -$330961.9.
  • Year-over-year, Net Cash Flow tumbled 1676.35% in 2022 and then skyrocketed 374.04% in 2026.
  • A 5-year view of Net Cash Flow shows it stood at $2.4 million in 2022, then increased by 27.37% to $3.0 million in 2023, then plummeted by 83.03% to $512147.0 in 2024, then tumbled by 1147.99% to -$5.4 million in 2025, then skyrocketed by 197.16% to $5.2 million in 2026.
  • Per Business Quant, the three most recent readings for IRMD's Net Cash Flow are $5.2 million (Q1 2026), -$5.4 million (Q4 2025), and $3.5 million (Q3 2025).